<p>BayBridge Capital Group LLC 在第三季度收購了強生（NYSE:JNJ - 免費報告）股票的新頭寸，根據其最近向證券交易委員會的備案。該基金收購了 6203 股公司股票，價值約 115 萬美元。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<ul>
<li>降息使這三隻收益 ETF 比以往更具吸引力</li>
</ul>
<p>其他幾家對沖基金最近也對 JNJ 的頭寸進行了調整。Clark Asset Management LLC 在第二季度將其在強生的股份增加了 51.6%。Clark Asset Management LLC 現在擁有 8884 股公司股票，價值 135.7 萬美元，此前在該期間又購買了 3025 股。北卡羅來納州財政部長在第二季度將其在強生的持股增加了 8.3%。北卡羅來納州財政部長現在擁有 1234945 股公司股票，價值 188,638,000 美元，此前在上個季度又收購了 94957 股。Avanza Fonder AB 在第二季度將其在強生的頭寸提高了 2.9%。Avanza Fonder AB 現在擁有 234647 股公司股票，價值 35842000 美元，此前在該期間又收購了 6566 股。Talbot Financial LLC 在第三季度將其在強生的持股提高了 4.6%。Talbot Financial LLC 現在擁有 138424 股公司股票，價值 25667000 美元，此前在上個季度又購買了 6143 股。最後，Winnow Wealth LLC 在第二季度收購了強生的新股份，價值約 295,000 美元。69.55% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師評級變動</h2>
<p>幾家研究公司最近對 JNJ 發表了評論。摩根士丹利將強生的目標價從 190.00 美元上調至 197.00 美元，並在 12 月 12 日的報告中給予該股票 “持平” 評級。巴克萊將強生的目標價從 176.00 美元上調至 197.00 美元，並在 12 月 2 日的研究報告中給予該公司 “持平” 評級。富國銀行將強生的目標價從 212.00 美元上調至 230.00 美元，並在 12 月 12 日的報告中給予該公司 “超配” 評級。花旗將強生的目標價從 215.00 美元上調至 232.00 美元，並在 12 月 11 日的研究報告中給予該股票 “買入” 評級。最後，BMO 資本市場在 12 月 11 日的研究報告中重申了對強生股票的 “跑贏大盤” 評級。四位投資分析師對該股票給予了強烈買入評級，十四位給予了買入評級，九位給予了持有評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，平均目標價為 210.25 美元。</p>
<ul>
<li>輝瑞加大對減肥藥的投資</li>
</ul>
<p><strong>查看我們關於 JNJ 的最新研究報告</strong></p>
<h2>強生的價格表現</h2>
<p>強生（NYSE:JNJ）股票在週五開盤時為 208.01 美元。該公司的 50 日簡單移動平均為 199.39 美元，200 日簡單移動平均為 180.50 美元。強生的 52 周低點為 140.68 美元，52 周高點為 215.18 美元。該公司的市值為 5011.4 億美元，市盈率為 20.08，市盈增長比率為 2.25，貝塔值為 0.36。該公司的速動比率為 0.80，流動比率為 1.07，債務與股本比率為 0.50。</p>
<ul>
<li>5 只醫療保健股票值得關注，因為行業輪動正在全面展開</li>
</ul>
<p>強生（NYSE:JNJ - 獲取免費報告）最近於 8 月 30 日發佈了季度財報。該公司報告季度每股收益為 2.26 美元。強生的淨利潤率為 27.26%，股本回報率為 32.73%。該公司在該季度的收入為 240.2 億美元。股票研究分析師預測，強生在當前年度將發佈 10.58 美元的每股收益。</p>
<h2>強生的股息公告</h2>
<p>該公司最近還宣佈了季度股息，已於 12 月 9 日支付。11 月 25 日的股東獲得了 1.30 美元的股息。該股息的除息日期為 11 月 25 日。這代表着每年 5.20 美元的股息和 2.5% 的股息收益率。強生的股息支付比率目前為 50.19%。</p>
<h2>關於強生</h2>
<p>（免費報告）</p>
<p>強生是一家總部位於新澤西州新布倫瑞克的跨國醫療保健公司，開發、製造和銷售廣泛的產品，涵蓋製藥、醫療設備和以前的消費健康產品。該公司由約翰遜家族於 1886 年創立，已發展成為一個在全球多個國家開展業務和銷售的全球醫療保健組織。</p>
<p>該公司的製藥業務主要在其揚森研究與開發組織下進行，專注於免疫學、傳染病、腫瘤學和神經科學等治療領域的處方藥。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>在 1 月 1 日之前將 1000 美元投入這隻股票 [不是 NVDA]</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓為戰爭做準備</li>
<li>奇怪的水晶金屬表現優於硅，最高可達 100 倍</li>
<li>來自奇怪的新 “AI 燃料” 的 33000% 繁榮？</li>
</ul>
<p><strong>想看看其他對沖基金持有的 JNJ 嗎？</strong> 訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 備案和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>BayBridge Capital Group LLC 在第三季度收購了 6,203 股強生，價值 1,150,000 美元。幾家對沖基金調整了在 JNJ 的持倉。分析師對 JNJ 給出了 “適度買入” 的共識評級，平均目標價為 210.25 美元。強生的股票開盤價為 208.01 美元，市值為 5,011.4 億美元。該公司宣佈季度股息為 1.30 美元，收益率為 2.5%</p>

<p>BayBridge Capital Group LLC acquired a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The fund acquired 6,203 shares of the company's stock, valued at approximately $1,150,000.</p>
<div class="lb-trans"><p>BayBridge Capital Group LLC 在第三季度收購了強生（NYSE:JNJ - 免費報告）股票的新頭寸，根據其最近向證券交易委員會的備案。該基金收購了 6203 股公司股票，價值約 115 萬美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><ul>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
</ul>
<div class="lb-trans"><ul>
<li>降息使這三隻收益 ETF 比以往更具吸引力</li>
</ul>
</div><p>Several other hedge funds have also recently made changes to their positions in JNJ. Clark Asset Management LLC raised its stake in shares of Johnson &amp; Johnson by 51.6% during the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company's stock worth $1,357,000 after buying an additional 3,025 shares during the period. Treasurer of the State of North Carolina increased its holdings in Johnson &amp; Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company's stock worth $188,638,000 after acquiring an additional 94,957 shares in the last quarter. Avanza Fonder AB raised its position in Johnson &amp; Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock worth $35,842,000 after acquiring an additional 6,566 shares during the period. Talbot Financial LLC lifted its holdings in Johnson &amp; Johnson by 4.6% during the third quarter. Talbot Financial LLC now owns 138,424 shares of the company's stock valued at $25,667,000 after purchasing an additional 6,143 shares in the last quarter. Finally, Winnow Wealth LLC acquired a new stake in shares of Johnson &amp; Johnson in the second quarter valued at about $295,000. 69.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也對 JNJ 的頭寸進行了調整。Clark Asset Management LLC 在第二季度將其在強生的股份增加了 51.6%。Clark Asset Management LLC 現在擁有 8884 股公司股票，價值 135.7 萬美元，此前在該期間又購買了 3025 股。北卡羅來納州財政部長在第二季度將其在強生的持股增加了 8.3%。北卡羅來納州財政部長現在擁有 1234945 股公司股票，價值 188,638,000 美元，此前在上個季度又收購了 94957 股。Avanza Fonder AB 在第二季度將其在強生的頭寸提高了 2.9%。Avanza Fonder AB 現在擁有 234647 股公司股票，價值 35842000 美元，此前在該期間又收購了 6566 股。Talbot Financial LLC 在第三季度將其在強生的持股提高了 4.6%。Talbot Financial LLC 現在擁有 138424 股公司股票，價值 25667000 美元，此前在上個季度又購買了 6143 股。最後，Winnow Wealth LLC 在第二季度收購了強生的新股份，價值約 295,000 美元。69.55% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several research firms have recently commented on JNJ. Morgan Stanley lifted their price target on Johnson &amp; Johnson from $190.00 to $197.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, December 12th. Barclays increased their price target on shares of Johnson &amp; Johnson from $176.00 to $197.00 and gave the company an &#34;equal weight&#34; rating in a research note on Tuesday, December 2nd. Wells Fargo &amp; Company upped their price objective on Johnson &amp; Johnson from $212.00 to $230.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, December 12th. Citigroup increased their price objective on Johnson &amp; Johnson from $215.00 to $232.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, December 11th. Finally, BMO Capital Markets restated an &#34;outperform&#34; rating on shares of Johnson &amp; Johnson in a research report on Thursday, December 11th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $210.25.</p>
<div class="lb-trans"><p>幾家研究公司最近對 JNJ 發表了評論。摩根士丹利將強生的目標價從 190.00 美元上調至 197.00 美元，並在 12 月 12 日的報告中給予該股票 “持平” 評級。巴克萊將強生的目標價從 176.00 美元上調至 197.00 美元，並在 12 月 2 日的研究報告中給予該公司 “持平” 評級。富國銀行將強生的目標價從 212.00 美元上調至 230.00 美元，並在 12 月 12 日的報告中給予該公司 “超配” 評級。花旗將強生的目標價從 215.00 美元上調至 232.00 美元，並在 12 月 11 日的研究報告中給予該股票 “買入” 評級。最後，BMO 資本市場在 12 月 11 日的研究報告中重申了對強生股票的 “跑贏大盤” 評級。四位投資分析師對該股票給予了強烈買入評級，十四位給予了買入評級，九位給予了持有評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，平均目標價為 210.25 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>輝瑞加大對減肥藥的投資</li>
</ul>
</div><p><strong>View Our Latest Research Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 JNJ 的最新研究報告</strong></p>
</div><h2>Johnson &amp; Johnson Price Performance</h2>
<div class="lb-trans"><h2>強生的價格表現</h2>
</div><p>Shares of NYSE:JNJ opened at $208.01 on Friday. The business has a fifty day simple moving average of $199.39 and a 200-day simple moving average of $180.50. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The company has a market cap of $501.14 billion, a P/E ratio of 20.08, a P/E/G ratio of 2.25 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ）股票在週五開盤時為 208.01 美元。該公司的 50 日簡單移動平均為 199.39 美元，200 日簡單移動平均為 180.50 美元。強生的 52 周低點為 140.68 美元，52 周高點為 215.18 美元。該公司的市值為 5011.4 億美元，市盈率為 20.08，市盈增長比率為 2.25，貝塔值為 0.36。該公司的速動比率為 0.80，流動比率為 1.07，債務與股本比率為 0.50。</p>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只醫療保健股票值得關注，因為行業輪動正在全面展開</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson &amp; Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. Equities research analysts forecast that Johnson &amp; Johnson will post 10.58 EPS for the current year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近於 8 月 30 日發佈了季度財報。該公司報告季度每股收益為 2.26 美元。強生的淨利潤率為 27.26%，股本回報率為 32.73%。該公司在該季度的收入為 240.2 億美元。股票研究分析師預測，強生在當前年度將發佈 10.58 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>強生的股息公告</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson &amp; Johnson's dividend payout ratio is presently 50.19%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度股息，已於 12 月 9 日支付。11 月 25 日的股東獲得了 1.30 美元的股息。該股息的除息日期為 11 月 25 日。這代表着每年 5.20 美元的股息和 2.5% 的股息收益率。強生的股息支付比率目前為 50.19%。</p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>關於強生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.</p>
<div class="lb-trans"><p>強生是一家總部位於新澤西州新布倫瑞克的跨國醫療保健公司，開發、製造和銷售廣泛的產品，涵蓋製藥、醫療設備和以前的消費健康產品。該公司由約翰遜家族於 1886 年創立，已發展成為一個在全球多個國家開展業務和銷售的全球醫療保健組織。</p>
</div><p>The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.</p>
<div class="lb-trans"><p>該公司的製藥業務主要在其揚森研究與開發組織下進行，專注於免疫學、傳染病、腫瘤學和神經科學等治療領域的處方藥。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
<li>Washington prepares for war</li>
<li>Strange Crystal Metal Outperforms Silicon Up to 100X</li>
<li>33,000% boom from weird new “AI Fuel?”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>在 1 月 1 日之前將 1000 美元投入這隻股票 [不是 NVDA]</li>
<li>將你的 “死錢” 轉變為每月 306 美元以上（從這個月開始）</li>
<li>華盛頓為戰爭做準備</li>
<li>奇怪的水晶金屬表現優於硅，最高可達 100 倍</li>
<li>來自奇怪的新 “AI 燃料” 的 33000% 繁榮？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding JNJ?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson &amp; Johnson (NYSE:JNJ - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 JNJ 嗎？</strong> 訪問 HoldingsChannel.com 獲取強生（NYSE:JNJ - 免費報告）的最新 13F 備案和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

BayBridge Capital Group LLC 購入了 6,203 股強生公司股票$JNJ